SCHEMBL5597012

SCHEMBL5597012

CC(C)(C)OC(=O)N1CCCC(N2CCc3cncc4ccc(Br)c2c34)C1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 2/20 0.44
CYP2C9 P11712 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
PIK3R1 P27986 1/20 0.37
PIK3CA P42336 1/20 0.37
USP30 Q70CQ3 5/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
HPGDS O60760 1/20 0.36
KDM1A O60341 1/20 0.36
HCAR1 Q9BXC0 1/20 0.36
TRPV3 Q8NET8 1/20 0.36
UCHL1 P09936 1/20 0.35
FGFR4 P22455 1/20 0.35
APLNR P35414 1/20 0.35
BTK Q06187 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5596601 0.95 USP30 (0.42) FPR2HDAC4HDAC6PIK3R1PIK3CA
SCHEMBL5597039 0.89 FPR2 (0.41) FPR2CYP2C9HDAC4HDAC6PIK3R1
SCHEMBL5597056 0.89 TP53 (0.41) FPR2
SCHEMBL5596376 0.84 FPR2 (0.44) FPR2CYP2C9HDAC4HDAC6PIK3R1
SCHEMBL5596812 0.84 PIK3CA (0.45) PIK3R1PIK3CAUSP30KDM1A
SCHEMBL5596980 0.84 USP30 (0.42) FPR2CYP2C9HDAC4HDAC6PIK3R1
SCHEMBL5597144 0.82 FPR2 (0.44) FPR2CYP2C9HDAC4HDAC6PIK3R1
SCHEMBL5596990 0.78 USP30 (0.40) FPR2PIK3R1PIK3CAUSP30BTK
SCHEMBL5596448 0.78 TP53 (0.41) PIK3R1PIK3CAKDM1A
SCHEMBL5596878 0.78 USP30 (0.47) PIK3R1PIK3CAUSP30PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1829876-A1 NITROGENEOUS TRICYCLIC COMPOUND Asahi Kasei Pharma Corporation (JP) 2007-09-05 EP disclosed
US-20060247266-A1 Nitrogen-containing tricyclic compounds ASAHI KASEI PHARMA CORPORATION (JP) 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247266-A1 Nitrogen-containing tricyclic compounds MYO1B, CHRM1, MYL12A FPR2 3865/4885CYP2C9 3893/4885HDAC4 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.